MIQNAF contains nafithromycin, which acts against a broad spectrum of gram-positive and gram-negative bacteria. It inhibits protein synthesis in bacterial cells, leading to their destruction. The drug is used for the treatment of bacterial infections in the respiratory tract, skin, soft tissues, and urinary tract infections. It is recommended for use in combination therapy and for preventing infections recurrence.
The product is used for:
Respiratory tract infections (pneumonia, bronchitis)
Skin and soft tissue infections (furuncles, abscesses)
Urinary tract infections
Gastrointestinal infections
Sepsis and other bacterial infections
MIQNAF is taken orally, 1 tablet (400 mg) 1-2 times a day, depending on the doctor’s prescription and the severity of the infection. The treatment usually lasts 7-14 days, depending on the type of infection and the patient’s condition.
Contraindications:
Hypersensitivity to nafithromycin or other components of the product
Severe liver or kidney diseases
Pregnancy and breastfeeding (under medical supervision)
Children under 12 years old (under medical supervision)
Side Effects:
Nausea, vomiting, dyspepsia
Allergic reactions (rash, itching)
Headache, dizziness
Liver dysfunction (rare cases)
Leukopenia, thrombocytopenia
